Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK119 + AK104 in Advanced Solid Tumors
NCT04572152Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2020
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of drebuxelimab in solid tumor, sponsored by Akeso, Inc. Primary endpoints: Adverse Events and Dose Limiting Toxicity. Started Dec 2020; status: completed.
02
Drugs
drebuxelimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04572152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572152.